| 18.55 0.36 (1.98%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.84  |
1-year : | 25.51 |
| Resists | First : | 18.7 |
Second : | 21.84 |
| Pivot price | 17.25 |
|||
| Supports | First : | 16.84 |
Second : | 15.69 |
| MAs | MA(5) : | 17.96 |
MA(20) : | 17.04 |
| MA(100) : | 15.7 |
MA(250) : | 14.86 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 86.8 |
D(3) : | 87.3  |
| RSI | RSI(14): 78.7 |
|||
| 52-week | High : | 18.7 | Low : | 12.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INVA ] has closed above the upper band by 4.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 124.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.72 - 18.79 | 18.79 - 18.85 |
| Low: | 18.09 - 18.18 | 18.18 - 18.25 |
| Close: | 18.42 - 18.55 | 18.55 - 18.66 |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Fri, 26 Jul 2024
Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price - Simply Wall St
Tue, 23 Jul 2024
Orion Portfolio Solutions LLC Has $1.39 Million Stock Position in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Mon, 22 Jul 2024
Innoviva (NASDAQ:INVA) Reaches New 12-Month High at $17.62 - MarketBeat
Sun, 21 Jul 2024
Westfield Capital Management Co. LP Decreases Stake in Innoviva, Inc. (NASDAQ:INVA) - MarketBeat
Wed, 17 Jul 2024
Innoviva (NASDAQ:INVA) shareholders have earned a 36% return over the last year - Yahoo Finance
Tue, 16 Jul 2024
Innoviva (NASDAQ:INVA) Upgraded to Strong-Buy by StockNews.com - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 120.5 (%) |
| Shares Short | 11,270 (K) |
| Shares Short P.Month | 12,230 (K) |
| EPS | 2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.21 |
| Profit Margin | 58.2 % |
| Operating Margin | 33.2 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 28.6 % |
| Qtrly Rev. Growth | 1.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.99 |
| EBITDA (p.s.) | 2.8 |
| Qtrly Earnings Growth | 10.3 % |
| Operating Cash Flow | 152 (M) |
| Levered Free Cash Flow | 130 (M) |
| PE Ratio | 8.28 |
| PEG Ratio | 0.7 |
| Price to Book value | 1.65 |
| Price to Sales | 3.71 |
| Price to Cash Flow | 7.59 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 1.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|